Plasma Fractionation Market to Gain Remarkable Traction through 2025

Posted by aartimurkute on September 23rd, 2021

Plasma-derived medical products have been used for decades to treat clinical diseases. Even though there are more than 30 plasma-derived medications, they are in short supply making them expensive. Several plasma protein concentrates such as gamma globulin to treat immunodeficiency and clotting factor concentrates to treat haemophilia are considered essential medicines by the WHO, ensuring bright prospects for the overall plasma fractionation market.

Get PDF Sample Copy of this Plasma Fractionation MarketReport:

https://www.fairfieldmarketresearch.com/report/plasma-fractionation-market/request-sample

Lack of Treatment of Haemophilia Makes Plasma Fractionation the Need of the Hour

WHO data suggests a wide chasm between the demand and supply of essential plasma products to treat different ailments. The World Federation of Haemophilia believes only a third of patients with haemophilia A or B are actually diagnosed and approx. a quarter receive proper treatment. In addition, less than a tenth of patients with primary immune deficiency are diagnosed and even less receive treatment. The WHO is seeking the implementation of GMP in blood establishments through the WHO Expert Committee on Biological Standardization to aid enhancement of NRA’s in the sector.

Protease Inhibitors Unlikely to Outpace Immunoglobin Segment in Plasma Fractionation Market

Immunoglobins accounted for the largest segment of the plasma fractionation market in 2019 as it is a popular treatment option in autoimmune and neurological conditions. Immunoglobins are used to treat chronic inflammatory demyelinating polyradiculoneuropathy and primary immune deficiencies. There has been a spike in the diagnostic rate of immune diseases recently due to massive investments in immunodeficiency research. Nonetheless, the protease inhibitor segment should record the highest growth rate during the forecast period, primarily as an antiviral agent. Increasing outbreaks of viruses such as SARS, MERS, and COVID-19 are anticipated to benefit demand for protease inhibitors in the plasma fractionation market.

Do You Have Any Query Or Specific Requirement? Request Customization of Report: https://www.fairfieldmarketresearch.com/report/plasma-fractionation-market/request-customization

Intense Competition And Product Launches Characterize Plasma Fractionation Market

Major companies in the plasma fractionation market are establishing dedicated plasma production units. For e.g. – Israeli biotech company Alishech has installed the largest blood plasma fractionation unit in Russia that will manufacture more than 25 types of dried plasma and drugs. In the US, Kendrion Biopharma received FDA authorization to setup a plasma production facility in the state of New York. Other players of note in the plasma fractionation market include CSL, Grifols, Shire, Octapharma, Kedrion, LFB , Biotest, Sanquin, China Biologic Products, Bio Products Laboratory, Japan Blood Products Organization, Green Cross Corporation, Shanghai RAAS Blood Products , Emergent BioSolutions , Intas Biopharmaceuticals , Bharat Serums and Vaccines Limited , SK Plasma, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., KabaFusion , and Centurion Pharma.

Convalescent Plasma Therapy Could be the Saving Grace for COVID-19 Affected Patients

COVID-19 has turned the global economy upside down and pharma companies and healthcare providers have been racing to develop treatments to target the novel variants of this infectious disease. Even though no specific drugs are currently on the horizon, convalescent plasma (CP) therapy has been encouraging in clinical trials of COVID-19 patients. Nodal agencies are now offering CP to their patients as clinical investigations on their safety and efficacy are underway. While CP has not been approved by the US FDA to treat COVID-19, it is regulated as an investigational product under emergency authorization for COVID-19 patients. Thus, the true impact of COVID-19 on the plasma fractionation market would largely depend on the outcome of the ongoing clinical trials.